PubMed Health⌕ Search

Biomedical subjects

K Musshoff

Publications and source records attributed to K Musshoff.

At least 19 recordsLinked to original sources
PubMed1985

[Diagnosis and therapy of Hodgkin's disease in Freiburg in Breisgau 1964 to 1976. 1. Report of the complete collective].

Between May 1964 and December 1976, 370 patients with Hodgkin's disease (CS/PSIn = 41 [11.2%], CS/PSIIn = 148 [40.2%], CS/PSIII n = 148 [40.2%], CS/PSIV n = 31 [8.4%] with different diagnoses were treated by different therapies, 250 out of them (67.5%) only by radiotherapy (local, extended, and total lymphoid irradiation), 115 (31%) by radiotherapy and chemotherapy, and five patients in stage IV (1.5%) only by chemotherapy. The first treatment divides the patients into three subgroups with significantly different prognoses: 1. a subgroup with complete remission assessed half a year after the end of therapy (n = 206 [58%]) and a healing rate of 96.2%; 2. a subgroup with partial remission (n = 62 [17.5%]) and a healing rate of 51.6%; 3. a subgroup without remission (n = 87 [24.5%]) and a healing rate of 4.2%. In case of recurrence after complete or partial remission, another complete and durable remission is achieved by subsequent therapy in about 85% of patients with preceding complete remission and statistically about 50% of patients with preceding partial remission. The overall five-year survival rate is 73.1%; a constant level of 67.3% (statistical healing rate) is observed after seven years. The following risk factors for remission have been found: the histologic manifestation lymphocytic depletion, parts of stage III, especially of type B, stage IV, and an age above 40 years and even more above 50 years.

Adolescent↗
PubMed1985

[Diagnosis and therapy of Hodgkin's disease in Freiburg in Breisgau 1964 to 1976. 2. Results during the treatment period 1972-1976 compared with the period 1964-1971].

The total group of patients with Hodgkin's disease submitted to primary treatment from May 1964 till December 1976 is divided with respect to diagnostics and therapy into a preponderantly clinically assessed group (CS) treated during the years of 1964 to 1971 (n = 190) and a preponderantly surgically assessed group (PS) treated during the years of 1972 to 1976 (n = 180). The first subgroup was treated with differently large irradiation fields and, in case of combined therapy, mostly with cyclophosphamide. The second subgroup was treated with extended fields, even until total lymphoid irradiation and, in case of drug administration, with primary combined chemotherapy (MOPP). The overall five-year remission rates of both subgroups (stages I to IV) have improved from 35.4% to 54.8% (P less than or equal to 0.001) and the five-year survival rates from 67.2% to 78.2% (P less than or equal to 0.001). If a complete remission was achieved, this was obtained, as far as judgeable, already at an earlier moment in the individual groups: e.g., in stage I with 95.5% after one year as against 94.1% after five years and in stage II with 91.3% after four years as against 72.9% after seven years. The prognostic differences of stages I and II and the histologic manifestations: lymphocytic predominance, nodular sclerosis, and mixed cellularity were equalized under the therapeutic measures of the intensive treatment period.

Adolescent↗
PubMed1977

[Primary and secondary exploratory laparotomy and splenectomy in Hodgkin's disease (author's transl)].

Exploratory laparotomy with splenectomy was performed on 275 patients with hisologically confirmed Hodgkin's disease. In 188 patients the laparotomy was a primary one to determine more precisely the state of the disease. A secondary laparotomy was performed in 87 patients 1-12 years after diagnosis and radiotherapy. In 17.5% of patients the state had to be revised after laparotomy with splenectomy. In 38 the disease had further progressed, while in ten it had slighty regressed. In four cases clinical stage I proved to be stage III. Even prognostically more favourable forms may have progressed at first diagnosis. There was no correlation between B-symptoms and histological type, but there was between B-symptoms and spread of the disease. Calculated spleen weight provided no clue as to spleen involvement. There was no clear relationship between spleen involvement and histological subclassification. Risk-effect analysis indicate that laparotomy with splenectomy was useful because it makes optimal treatment possible.

Adult↗
PubMed1976

Preliminary clinical findings on the Kiel classification of malignant lymphomas.

In 75 patients with non-Hodgkin Lymphomas the influence of the histopathological form, as judged by the Kiel classification, on the epidemiology and prognosis of the disease was examined retrospectively. The different forms of the Kiel classification influence in a typical way the age specific incidence rates and the prognosis of the disease.

Adolescent↗
PubMed1976

The prognostic significance of first and second remission after first and second relapse radiotherapy in Hodgkin's disease.

New aspects concerning the prognostic importance of remission following first treatment and second relapse treatment have resulted from a retrospective study of 175 patients who received primary treatment for Hodgkin's disease between 1964 and 1971. By means of renewed radiotherapy 27 out of 66 (=41%) patients were again brought to full remission with 10 of the 66 (=15%) patients reaching partial remission. The prognosis of the second full remission is equal to that of the first full remission, the prospect of cure being retained. The prognosis of relapse patients following renewed radiotherapy is dependent on: 1. the type of the previous remission, whether full or partial, 2. the localization of the recidive, 3. the primary stage and the presence (or absence) of signs of activity B, 4. the histology, and 5. the age of the patient.

Adolescent↗
PubMed1975

Proceedings: Prognosis of non-Hodgkin's lymphomas with special emphasis on the staging classification.

The prognosis of the non-Hodgkin's lymphomas is determined by 1. the pattern of origin and spread which can be demonstrated in a staging classification, 2, the histopathological type, and 3. the effectiveness and scope of the treatment methods, particularly radio- and chemo-therapy. In the following paper the Ann Arbor Classification, which was originally conceived of for both disease groups (Hodgkin's and non-Hodgkin's lymphomas), is discussed particularly with respect to the applicability and prognostic evaluation for the non-Hodgkin's lymphomas. The Ann Arbor Classification may in essence reflect the oncological characteristics of the non-Hodgkin's accurately; there are, however, a number of findings with qualitative and quantitative differences which defy integration into the Ann Arbor Classification. The qualitative differences consist of the differing lymphatic and extralymphatic origins and their consequence for spread and prognosis. The quantitative differences refer to the varying patterns of distribution of the different stages of spreading, whereby the dissemination stages in the non-Hodgkin's lymphomas are more dependent on the histological form than is the case with the Hodgkin's lymphomas, and thus must play a greater role in the prognostic evaluation and indication for treatment. Suggestions have been made for a modification of the Ann Arbor Staging Classification for the non-Hodgkin's lymphomas.

Humans↗
PubMed1975

Prognostic significance of primary site after radiotherapy in non-Hodgkin's lymphomata.

In contrast to Hodgkin's lymphomata, non-Hodgkin's lymphomata originate in approximately a fourth of the cases in extranodal organs and sites. The prognosis of patients with primary extranodal organ involvement of the non-Hodgkin's lymphomata is similar to that of patients with primary lumph node involvement of the Hodgkin's and non-Hodgkin's lymphomata, dependent on the special spreading of the disease corresponding to the 4 stages of the Ann Arbor classification. This applies to the primary involvement of a single lymph node region (Stage I) or a single extralymphatic organ or site (stage IE) as well as to further stages of spreading within the lymphatic system (Stages II and III) including secondary localized involvement of an extralymphatic organ and site (Stages IIE and IIIE). The same qualitative dependence of the prognosis of Hodgkin's and non-Hodgkin's lymphomata on the spatial spreading, corresponding to the Ann Arbor concept, legitimizes, in spite of some quantitative differences, the application of the Ann Arbor classification system to all malignant lymphomata.

Hodgkin Disease↗